85 FR 123 pg. 38147 - Government-Owned Inventions; Availability for Licensing
Type: NOTICEVolume: 85Number: 123Page: 38147
Page: 38147FR document: [FR Doc. 2020-13656 Filed 6-24-20; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: National Institutes of Health
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY:
National Institutes of Health, HHS.
ACTION:
Notice.
SUMMARY:
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained by emailing Michael Shmilovich, shmilovm@nih.gov , the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Liposome Nanodecoys That Protect Against SARS-COV-2
Available for licensing and commercial development are patent rights covering a liposomal vesicle (a "nanodecoy") with a lipid bilayer with one or more proteins recognized by a pathogen ( e.g., SARS-CoV-2) and one or more cytokine receptors (such as IL-6; receptors: CD126, CD130; IL-1; receptors: CD121a, CD121b, IL-8; receptors: IL-8RB; IL-12; receptors: CD212; TNF-a; receptors: CD120a, CD120b; IFN-?; receptors: CD119, IFN-a/ß; receptors: CD118) and wherein the liposomal vesicle is non-replicating. Nanodecoys that display angiotensin-converting enzyme 2 (ACE2) and multiple cytokine receptors, are able to sequester SARS-CoV-2 and inhibit viral replication and infection, as well as to mitigate COVID-19-induced cytokine release syndrome (CRS) in susceptible cells.
Potential Commercial Applications:
• COVID-19
• SARS-CoV-2
• Cytokine release syndrome
? immunosuppression
• Viral inhibition
? Receptor binding competition
Development Stage:
• Preclinical
Inventors: Xiaoyuan (Shawn) Chen (NIBIB) and Lang Rao (NIBIB).
Intellectual Property: HHS Reference No. E-144-2020-0-US-01 "Engineered Cell Membrane Nanodecoys To Protect Against COVID-19;" U.S. Provisional Patent Application 63/038,380 filed June 12, 2020.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; shmilovm@mail.nih.gov.
Dated: June 17, 2020.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.
[FR Doc. 2020-13656 Filed 6-24-20; 8:45 am]
BILLING CODE 4140-01-P